Brokers Issue Forecasts for RLAY Q1 Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Relay Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.63) for the quarter. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share.

A number of other brokerages have also weighed in on RLAY. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target on shares of Relay Therapeutics in a research note on Thursday, December 12th. Leerink Partners decreased their price target on shares of Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Relay Therapeutics in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $20.50.

Relay Therapeutics Trading Down 6.4 %

Shares of Relay Therapeutics stock opened at $4.22 on Friday. The firm has a market capitalization of $706.36 million, a PE ratio of -1.62 and a beta of 1.61. Relay Therapeutics has a twelve month low of $3.50 and a twelve month high of $11.16. The firm’s 50-day moving average price is $4.51 and its 200 day moving average price is $5.97.

Relay Therapeutics (NASDAQ:RLAY) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.14. The business’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.54) earnings per share.

Institutional Trading of Relay Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC increased its holdings in Relay Therapeutics by 160.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 6,500 shares of the company’s stock valued at $27,000 after purchasing an additional 4,000 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Relay Therapeutics in the 3rd quarter valued at approximately $63,000. Portland Investment Counsel Inc. acquired a new stake in Relay Therapeutics in the 3rd quarter valued at approximately $71,000. Values First Advisors Inc. acquired a new stake in Relay Therapeutics in the 3rd quarter valued at approximately $75,000. Finally, E Fund Management Co. Ltd. increased its holdings in Relay Therapeutics by 52.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 17,654 shares of the company’s stock valued at $73,000 after purchasing an additional 6,104 shares during the last quarter. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Transactions at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 36,036 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $4.63, for a total transaction of $166,846.68. Following the completion of the sale, the chief financial officer now owns 263,190 shares in the company, valued at $1,218,569.70. This trade represents a 12.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Rahmer sold 32,156 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $4.15, for a total transaction of $133,447.40. Following the sale, the insider now owns 357,507 shares of the company’s stock, valued at $1,483,654.05. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 354,646 shares of company stock worth $1,672,757 in the last 90 days. Insiders own 4.32% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.